
Margaret D Weiss

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1511009/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Association between ADHD and the Severity of COVID-19 Infection. Journal of Attention Disorders, 2022, 26, 491-501.	1.5	27
2	Defragmenting the path to diagnosis for underserved youth with Autism Spectrum Disorder in a community-based health system. Healthcare, 2022, 10, 100597.	0.6	1
3	Catatonia with Psychosis in an 8-Year-Old Child: A Case Report and a Literature Review. Case Reports in Psychiatry, 2022, 2022, 1-5.	0.2	1
4	Clinical and Socio-Demographic Variables Associated with the Diagnosis of Long COVID Syndrome in Youth: A Population-Based Study. International Journal of Environmental Research and Public Health, 2022, 19, 5993.	1.2	24
5	Efficacy and Safety of PRC-063, Extended-Release Multilayer Methylphenidate in Adults with ADHD Including 6-Month Open-Label Extension. Journal of Attention Disorders, 2021, 25, 1417-1428.	1.5	15
6	Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension. CNS Drugs, 2021, 35, 667-679.	2.7	7
7	Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension. Journal of Child and Adolescent Psychopharmacology. 2021, 31, 610-622.	0.7	7
8	Effect of a Multilayer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trial Followed by a 6-Month Open-Label Follow-Up. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 623-630.	0.7	6
9	The Functional Impact of Sleep Disorders in Children With ADHD. Journal of Attention Disorders, 2020, 24, 499-508.	1.5	55
10	Characteristics of ADHD Symptom Response/Remission in a Clinical Trial of Methylphenidate Extended Release. Journal of Clinical Medicine, 2019, 8, 461.	1.0	13
11	Symptom Profiles Specific to Trauma in a Child Inpatient Unit. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, 818-820.e1.	0.3	1
12	Validation of the French Version of the Weiss Functional Impairment Rating Scale–Self-Report in a Large Cohort of Adult Patients With ADHD. Journal of Attention Disorders, 2019, 23, 1148-1159.	1.5	7
13	Parent and Child ADHD Symptoms in Relation to Parental Attitudes and Parenting: Testing the Similarity-Fit Hypothesis. Journal of Clinical Child and Adolescent Psychology, 2018, 47, S127-S136.	2.2	23
14	Stimulant â€~rapid metabolizers': wrong label, real phenomena. ADHD Attention Deficit and Hyperactivity Disorders, 2018, 10, 113-118.	1.7	7
15	Estimating minimal important differences for several scales assessing function and quality of life in patients with attention-deficit/hyperactivity disorder. CNS Spectrums, 2017, 22, 31-40.	0.7	15
16	Psychometric properties of the Japanese version of the Weiss Functional Impairment Rating Scale: Self-Report. ADHD Attention Deficit and Hyperactivity Disorders, 2017, 9, 169-177.	1.7	10
17	The Weiss Functional Impairment Rating Scale-Parent Form for assessing ADHD: evaluating diagnostic accuracy and determining optimal thresholds using ROC analysis. Quality of Life Research, 2017, 26, 1879-1885.	1.5	38
18	Long-Term Effects of Stimulant Treatment for ADHD: What Can We Tell Our Patients?. Current Developmental Disorders Reports, 2015, 2, 1-9.	0.9	16

MARGARET D WEISS

#	Article	IF	CITATIONS
19	New Research on the Complex Interaction of Sleep and ADHD. Current Sleep Medicine Reports, 2015, 1, 114-121.	0.7	18
20	Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial. CNS Drugs, 2015, 29, 953-962.	2.7	19
21	Turkish validity and reliability study of the Weiss Functional Impairment Rating Scale-Parent Report. ADHD Attention Deficit and Hyperactivity Disorders, 2015, 7, 129-139.	1.7	26
22	In Search of "Anything That Would Help― Journal of Attention Disorders, 2014, 18, 395-401.	1.5	14
23	The Effects of Instructions on Mothers' Ratings of Attention-Deficit/Hyperactivity Disorder Symptoms in Referred Children. Journal of Abnormal Child Psychology, 2014, 42, 479-488.	3.5	6
24	Review: limited evidence that risperidone reduces aggression and conduct problems in the short term in children and adolescents with disruptive behaviour disorders. Evidence-Based Mental Health, 2013, 16, 69-69.	2.2	2
25	Future Research Directions in Sleep and ADHD. Journal of Attention Disorders, 2013, 17, 550-564.	1.5	122
26	Evidence for a General Factor Model of ADHD in Adults. Journal of Attention Disorders, 2012, 16, 635-644.	1.5	57
27	Treatment of Catatonia with Electroconvulsive Therapy in Adolescents. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 96-100.	0.7	15
28	ADHD Treatments, Sleep, and Sleep Problems: Complex Associations. Neurotherapeutics, 2012, 9, 509-517.	2.1	119
29	Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. Journal of Psychopharmacology, 2012, 26, 753-765.	2.0	162
30	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Annals of Clinical Psychiatry, 2012, 24, 23-37.	0.6	74
31	The Effects of Instructions on Mothers' Ratings of Child Attention-Deficit/Hyperactivity Disorder Symptoms. Journal of Abnormal Child Psychology, 2011, 39, 1099-1110.	3.5	6
32	The screens culture: impact on ADHD. ADHD Attention Deficit and Hyperactivity Disorders, 2011, 3, 327-334.	1.7	97
33	Inattention, working memory, and academic achievement in adolescents referred for attention deficit/hyperactivity disorder (ADHD). Child Neuropsychology, 2011, 17, 444-458.	0.8	124
34	Clinical Correlates of Oppositional Defiant Disorder and Attention-Deficit/Hyperactivity Disorder in Adults. Postgraduate Medicine, 2011, 123, 177-184.	0.9	15
35	Time Course and Predictors of Health-Related Quality of Life Improvement and Medication Satisfaction in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder Treated with the Methylphenidate Transdermal System. Journal of Child and Adolescent Psychopharmacology, 2010, 20, 355-364.	0.7	14
36	Sleep Problems in the Child with Attention-Deficit Hyperactivity Disorder. CNS Drugs, 2010, 24, 811-828.	2.7	73

#	Article	IF	CITATIONS
37	A Naturalistic Study of Predictors and Risks of Atypical Antipsychotic Use in an Attention-Deficit/Hyperactivity Disorder Clinic. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 575-582.	0.7	33
38	Editorial. Journal of Attention Disorders, 2009, 12, 391-393.	1.5	4
39	HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. Current Medical Research and Opinion, 2009, 25, 3001-3010.	0.9	23
40	A randomized, placeboâ€controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. Journal of Pineal Research, 2008, 44, 57-64.	3.4	204
41	Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug and Alcohol Dependence, 2008, 96, 145-154.	1.6	151
42	Sleep Hygiene for Children With Neurodevelopmental Disabilities. Pediatrics, 2008, 122, 1343-1350.	1.0	177
43	Maintenance Study for Adolescent Depression. Journal of Child and Adolescent Psychopharmacology, 2008, 18, 389-394.	0.7	31
44	Psychiatric Comorbidity in ADHD Symptom Subtypes in Clinic and Community Adults. Journal of Attention Disorders, 2007, 11, 114-124.	1.5	74
45	Once-Daily Multilayer-Release Methylphenidate in a Double-Blind, Crossover Comparison to Immediate-Release Methylphenidate in Children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2007, 17, 675-688.	0.7	20
46	ODD, ADHD, Versus ODD+ADHD in Clinic and Community Adults. Journal of Attention Disorders, 2007, 11, 374-383.	1.5	28
47	Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat. Current Pediatric Reviews, 2007, 3, 214-224.	0.4	33
48	Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2007, 21, 10-41.	2.0	232
49	ADHD By Night: Sleep Problems and ADHD Medications. Child and Adolescent Psychopharmacology News, 2007, 12, 1-5.	0.1	6
50	Longâ€ŧerm effectiveness outcome of melatonin therapy in children with treatmentâ€resistant circadian rhythm sleep disorders. Journal of Pineal Research, 2007, 43, 351-359.	3.4	104
51	Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults. Current Psychiatry Reports, 2007, 9, 420-426.	2.1	69
52	Efficacy of a Novel Biphasic Controlled-Release Methylphenidate Formula in Adults With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychiatry, 2007, 68, 268-277.	1.1	48
53	A chart review study of the Inattentive and Combined Types of ADHD. Journal of Attention Disorders, 2003, 7, 1-9.	1.5	113
54	Effects of stimulant medication treatment on mothers' and children's attributions for the behavior of children with attention deficit hyperactivity disorder. Journal of Abnormal Child Psychology, 2000, 28, 371-382.	3.5	45

#	Article	IF	CITATIONS
55	The Role of the Alliance in the Pharmacologic Treatment of Depression. Journal of Clinical Psychiatry, 1997, 58, 196-204.	1.1	61
56	Combined Treatment With Moclobemide and Methylphenidate for Comorbid Major Depression and Adult Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology, 1996, 16, 468-469.	0.7	12
57	A comparison of the families of mothers with borderline and nonborderline personality disorders. Comprehensive Psychiatry, 1995, 36, 157-163.	1.5	58